HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 1, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Gabriela Rosu, M.D., has been named the company's first chief medical officer (CMO), effective November 7, 2016. In this newly created executive role, Dr. Rosu will oversee the strategy and execution of the company's expanding clinical portfolio of programs. She will lead the clinical efforts to develop the Company's DepoVax™-based product candidates in immuno-oncology and infectious diseases.
"We have reached an exciting point at Immunovaccine, as, with the recent progress of our clinical programs, we are rapidly approaching key milestones," said Frederic Ors, Immunovaccine's Chief Executive Officer. "The clinical and commercial experience that Gabriela brings to our team will be instrumental in preparing for our expansion and validates the potential of our platform and product candidates. We are thrilled to welcome her to our team, and believe that the depth and breadth of her medical knowledge, as well as her industry track record, are tremendous assets to our organization."
Dr. Rosu brings to Immunovaccine more than 15 years of broad clinical and pharmaceutical industry experience that spans the entire value chain of pharmaceutical development, from early-phase discovery to post-marketing commercialization. Most recently, Dr. Rosu was appointed the Medical Science Liaison, Haematology Oncology, at Janssen Inc., where she was responsible for the regional medical strategy implementation for targeted and immuno-modulating therapy in chronic lymphocytic leukemia (CLL) and multiple myeloma. Prior to this position, she served as the Global Medical Advisor in Haematology at Novo Nordisk, where she actively participated in developing the global medical strategy and clinical development plans for multiple compounds. Her duties included overseeing clinical trial planning, activities and publications for early development-phase compounds, as well as regulatory filing support and post-approval commitments for late-stage candidates and marketed products. Her experience in these positions included developing and implementing medical programs and participating in the development and review of medical and marketing materials. She played instrumental roles in international advisory boards, organized collaborations with research partners, and networked with key opinion leaders in support of her programs.
"I welcome the opportunity to join Immunovaccine, an organization with the potential to profoundly transform the way we approach the treatment of cancer," stated Dr. Rosu. "Immunovaccine is a pioneer in immuno-oncology, initiating one of the first combination trials in the field in 2011, when immuno-oncology was still in its infancy. Today, we understand much more clearly how our immune system has the ability to battle cancers when we can program it with the right instructions. Immunovaccine has developed what I believe to be among the most promising technology and product candidates to achieve just that, and I'm very excited about becoming part of the team who can make it available to patients, safely and effectively, across the world."
Prior to her work at Novo Nordisk, Dr. Rosu held various positions of increasing responsibility in organizations including GlaxoSmithKline, Berlex, Celgene, and Lundbeck Canada. Dr. Rosu started her career as Medical Doctor in Europe, practicing family medicine and emergency medicine after an internship in emergency surgery, obstetrics, and pediatrics. She received her Medical Doctor degree in 1995 from the Medical and Pharmaceutical University "Gr.T. Popa" in Iasi, Romania.
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as part of a triple combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline, including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management of the Company on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the results and successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by applicable law.